Search

Search Constraints

You searched for: Author/Creator Mishima, Hideyuki

Search Results

1. Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer. Issue 1 (December 2015)

2. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. (January 2018)

3. Level of arterial ligation in sigmoid colon and rectal cancer surgery. Issue 1 (December 2016)

4. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. Issue 1 (December 2015)

5. Multicenter, single‐arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild‐type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell‐free DNA. Issue 12 (5th July 2022)

6. NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome. Issue 6 (29th June 2022)

7. Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study. (July 2022)

8. Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study). (3rd August 2020)

9. Phase II study of S‐1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. Issue 10 (9th September 2017)

10. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study. Issue 6 (2nd June 2016)